What is the debt of Exelixis this year?
Exelixis has a debt level of -262.99 USD this year.
Exelixis Debt 2024
Exelixis Debt
-262.99 USD
Ticker
EXEL
ISIN
US30161Q1040
WKN
936718
In 2024, Exelixis's total debt was -262.99 USD, a -47.53% change from the -501.2 USD total debt recorded in the previous year.
Exelixis Aktienanalyse
What does Exelixis do?
Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding Exelixis's Debt Structure
Exelixis's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing Exelixis's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to Exelixis’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in Exelixis’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about Exelixis stock
What was the debt of Exelixis compared to the previous year?
The debt of Exelixis has increased by -47.53% compared to the previous year dropped.
What are the consequences of high debt for investors in Exelixis?
High debt can pose a risk for investors of Exelixis, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of Exelixis?
Low debt means that Exelixis has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from Exelixis affect the company?
An increase in debt of Exelixis can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of Exelixis affect the company?
A reduction in debt of Exelixis can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of Exelixis?
Some factors that can influence the debt of Exelixis include investments, acquisitions, operating costs, and revenue development.
Why are the debts of Exelixis so important for investors?
The debts of Exelixis are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can Exelixis take to change the debt?
To change the debt, Exelixis can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does Exelixis pay?
Over the past 12 months, Exelixis paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Exelixis is expected to pay a dividend of 0 USD.
What is the dividend yield of Exelixis?
The current dividend yield of Exelixis is .
When does Exelixis pay dividends?
Exelixis pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Exelixis?
Exelixis paid dividends every year for the past 0 years.
What is the dividend of Exelixis?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Exelixis located?
Exelixis is assigned to the 'Health' sector.
Wann musste ich die Aktien von Exelixis kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Exelixis from 7/31/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/31/2024.
When did Exelixis pay the last dividend?
The last dividend was paid out on 7/31/2024.
What was the dividend of Exelixis in the year 2023?
In the year 2023, Exelixis distributed 0 USD as dividends.
In which currency does Exelixis pay out the dividend?
The dividends of Exelixis are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Exelixis
Our stock analysis for Exelixis Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Exelixis Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
